AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management.
The AAAAI Mast Cell Disorders Committee Work Group Report provides updated recommendations for the diagnosis and management of primary mast cell activation syndrome (MCAS). It highlights the importance of identifying systemic anaphylaxis promptly, regardless of whether it's triggered by allergens or other pathways. The report emphasizes the use of specific biomarkers that can help distinguish MCAS from other conditions and identifies therapeutic drugs that might target these mediators or mast cells directly. The report also suggests that genetic mutations, whether familial or somatic, could be important diagnostic tools and may point to new treatment options targeting these mutations or related pathways. The guidelines aim to offer clinicians practical criteria with high sensitivity and specificity to correctly diagnose MCAS and avoid overdiagnosis in patients who may have different disorders.
Published September 03, 2019
